Valuence Merger I in an amended proxy said it has adjusted a proposed deadline extension to run until March 3, 2026, rather than a deadline of September 2025 as outlined in the initial proxy filing.
Valuence I lost more than two-thirds of its shares outstanding to redemptions in connection with the last extension vote a year ago.
The SPAC completed a $200 million IPO in March 2022. Since then, it has focused on life sciences targets based in Asia, though excluding China, Hong Kong and Macau. Valuence I has yet to announce a deal. Read more.
